In vitro activity of sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 63, Issue 1, 2019, Pages

  Karlowsky, James A ^a   Adam, Heather J ^a   Baxter, Melanie R ^a   Denisuik, Andrew J ^a   Lagacé Wiens, Philippe R S ^a   Walkty, Andrew J ^a   Puttagunta, Sailaja ^b   Dunne, Michael W ^b   Zhanel, George G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Iterum Therapeutics   (United States)

Author keywords

Escherichia coli; Penem; Sulopenem; Urinary

Indexed keywords

BETA LACTAMASE AMPC; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; SULOPENEM; ANTIINFECTIVE AGENT; LACTAM;

ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CANADIAN; DRUG ACTIVITY; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; CANADA; DRUG EFFECT; ESCHERICHIA COLI INFECTION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CANADA; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; LACTAMS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; RETROSPECTIVE STUDIES; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; URINARY TRACT INFECTIONS;

EID: 85058916856     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01832-18     Document Type: Article

References (29)

1. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. 2011. International clinical practice guidelines for the treatment of uncomplicated acute cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103– e120. https://doi.org/10.1093/cid/ciq257.
2. Nicolle LE. 2002. Epidemiology of urinary tract infections. Clin Microbiol Newsl 24:135–140. https://doi.org/10.1016/S0196-4399(02)80035-6.
3. Foxman B. 2014. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 28:1–13. https://doi.org/10.1016/j.idc.2013.09.003.
4. Echols RM, Tosiello RL, Haverstock DC, Tice AD. 1999. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis 29:113–119. https://doi.org/10.1086/520138.
5. Karlowsky JA, Lagacé-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, Hoban DJ, Zhanel GG. 2011. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother 55:3169–3175. https://doi.org/10.1128/AAC.00066-11.
6. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. 2012. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 56:2181–2183. https://doi.org/10.1128/AAC.06060-11.
7. Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF. 2016. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014. Diagn Microbiol Infect Dis 85:459–465. https://doi.org/10.1016/j.diagmicrobio.2016.04.022.
8. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM. 2016. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 37:1288 –1301. https://doi.org/10.1017/ice.2016.174.
9. Zhanel GG, Walkty AJ, Karlowsky JA. 2016. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol 2016:1. https://doi.org/10.1155/2016/2082693.
10. Puttagunta S, Dunne M. 2017. Antimicrobial activity of sulopenem against Gram-positive and Gram-negative organisms from the United States and Europe (2013–2015), abstr Saturday-296. Abstr ASM Microbe 2017.
11. Puttagunta S, Gupta V, Murray J, Dunne M. 2017. Prevalence of extended-spectrum beta-lactamase producing and quinolone nonsusceptible Enterobacteriaceae in inpatient and outpatient settings in the USA from 2011–2017, abstr 400. Abstr ID Week 2017.
12. ClinicalTrials.gov. 2018. U.S. National Library of Medicine, Bethesda, MD. https://clinicaltrials.gov/ct2/results?termsulopenem&SearchSearch. Accessed 10 July 2018.
13. Minamimura M, Taniyama Y, Inoue E, Mitsuhashi S. 1993. In vitro antibacterial activity and -lactamase stability of CP-70,429, a penem antibiotic. Antimicrob Agents Chemother 37:1547–1551. https://doi.org/10.1128/AAC.37.7.1547.
14. Centers for Disease Control and Prevention. 2018. Biggest threats and data. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/drugresistance/biggest_threats.html.
15. Zhanel GG, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens P, Walkty A, Hoban DJ, Puttagunta S, Dunne M, Karlowsky JA. 2018. In vitro activity of sulopenem, an oral penem, against Escherichia coli isolated from urine specimens of patients across Canada in 2014-2016, abstr Sunday-568. Abstr ASM Microbe 2018.
16. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol K, Denisuik A, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ. 2013. Antimicrobial susceptibility of 22,746 pathogens from Canadian hospitals: results of the CANWARD 2007–2011 study. J Antimicrob Chemother 68(Suppl 1):7–22.
17. Clinical and Laboratory Standards Institute. 2008. Abbreviated identification of bacteria and yeasts—2nd ed. CLSI document M35-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—11th ed. CLSI document M07. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 28th informational supplement. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PRS, Adam HJ, Hoban DJ. 2011. Prevalence and characterization of extended-spectrum -lactamase- and AmpC -lactamase-producing Escherichia coli: results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis 69:326–334. https://doi.org/10.1016/j.diagmicrobio.2010.10.029.
21. Denisuik AJ, Lagacé-Wiens PRS, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG. 2013. Molecular epidemiology of extended-spectrum -lactamase-, AmpC -lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother 68(Suppl 1):i57–i65.
22. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
23. Gootz T, Retsema J, Girard A, Hamanaka E, Anderson M, Sokolowski S. 1989. In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother 33:1160 –1166. https://doi.org/10.1128/AAC.33.8.1160.
24. Aronin S, Huband M, Flamm R, Puttagunta S, Dunne M. 2018. Sulopenem activity against Enterobacteriaceae isolates from patients with urinary tract infections, abstr Sunday-569. Abstr ASM Microbe 2018.
25. Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC. 2009. Comparative antipneumococcal activities of sulopenem and other drugs. Antimicrob Agents Chemother 53:2239–2247. https://doi.org/10.1128/AAC.01531-08.
26. Ednie LM, Appelbaum PC. 2009. Antianaerobic activity of sulopenem compared to six other agents. Antimicrob Agents Chemother 53: 2163–2170. https://doi.org/10.1128/AAC.01557-08.
27. Okamoto K, Gotoh N, Nishino T. 2001. Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob Agents Chemother 45: 1964–1971. https://doi.org/10.1128/AAC.45.7.1964-1971.2001.
28. Duignan J, Mullins L, Brennan L, Huband M, Cohen M, Pagano P, Murray R, McCurdy S, Gootz T. 2008. In vitro antibacterial activity of sulopenem: a new oral penem antimicrobial versus recent bacterial clinical isolates, abstr F1-344. Abstr Infect Dis Soc Am (IDSA) 46th Annu Meet.
29. Dunne M, Morrissey I, De Piano C, Magnet S, Hawser S, Puttagunta S. 2018. Antimicrobial activity of sulopenem in the urine of healthy volunteers, abstr P1527. Abstr ECCMID 2018.